Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays are capable of detecting the new variant strain Omicron Variant correctly
In response to the new variant strain Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on November 29th, 2021. According to our analysis, we confirm that our SARS-CoV-2 […]
